NOF (4403) Q2 2025 earnings summary

Executive summary

• Net sales for H1 FY2024 rose 8.5% year-over-year to ¥110.5 billion, with operating profit up 16.3% to ¥23.3 billion, driven by strong Functional Chemicals and steady Explosives & Propulsion segments.

• Pharmaceuticals, Medicals and Health segment saw a temporary leveling off in demand, leading to a decline in both sales and profit.

• The company advanced its 2025 Mid-Term Management Plan, focusing on business expansion in life and healthcare, environment and energy, and electronics and IT.

• Despite global economic uncertainty, domestic conditions showed gradual recovery, though risks from high prices and foreign exchange volatility persisted.

Financial highlights

• H1 FY2024 net sales: ¥110.5 billion (+8.5% YoY); operating profit: ¥23.3 billion (+16.3% YoY); net income: ¥17.0 billion (+4.2% YoY).

• Gross margin improved to 38.5% from 37.4% YoY; gross profit increased to ¥42.5 billion.

• Free cash flow for H1 FY2024 was ¥7.4 billion, up from ¥6.7 billion YoY.

• Cash and deposits increased by ¥3.2 billion to ¥94.9 billion as of September 30, 2024.

• Total assets as of September 30, 2024 were ¥353.0 billion, with net assets at ¥277.8 billion and an equity-to-asset ratio of 78.4%.

Outlook and guidance

• Full-year FY2024 net sales forecast revised upward to ¥239.0 billion (+3.0% to +7.5% YoY); operating profit to ¥43.0 billion (+2.0% to +6.2% YoY); net income to ¥34.9 billion (+2.7% to +5.8% YoY).

• Annual dividend forecast raised to ¥42 per share, reflecting the share split and progressive dividend policy.

• Share buyback of up to ¥5 billion (up to 2.5 million shares) planned between November and December 2024, targeting a total return ratio of 50% in line with the mid-term plan.

• The company notes actual results may differ from forecasts due to various factors.